Showing results (161-170 of 302) with videos related to
Sort By:
Pageof 31
Frontiers in Oncology|March 18, 2021
Case Report: Combined CDK4/6 and MEK Inhibition in Refractory CDKN2A and NRAS Mutant MelanomaAndrea Forschner, Tobias Sinnberg, Gabi Mroz, et al.European Journal of Cancer (Oxford, England : 1990)|January 23, 2024
The side effect registry immuno-oncology (SERIO) - A tool for systematic analysis of immunotherapy-induced side effectsCarolin Ertl, Theresa Ruf, Dirk Mentzer, et al.Journal for Immunotherapy of Cancer|July 14, 2019
Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker studyAndrea Forschner, Florian Battke, Dirk Hadaschik, et al.Frontiers in Oncology|August 30, 2021
Apoptotic Gastritis in Melanoma Patients Treated With PD-1-Based Immune Checkpoint Inhibition - Clinical and Histopathological Findings Including the Diagnostic Value of Anti-Caspase-3 ImmunohistochemistryJan-Malte Placke, Josefine Rawitzer, Henning Reis, et al.European Journal of Cancer (Oxford, England : 1990)|March 13, 2024
The RANKL inhibitor denosumab in combination with dual checkpoint inhibition is associated with increased CXCL-13 serum concentrationsKatrin Schaper-Gerhardt, Ralf Gutzmer, Yenny Angela, et al.Cancer Imaging : the Official Publication of the International Cancer Imaging Society|February 6, 2022
Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanomaJustin Ferdinandus, Anne Zaremba, Lisa Zimmer, et al.Journal for Immunotherapy of Cancer|May 31, 2019
Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?Anne Zaremba, Eleftheria Chorti, Finja Jockenhöfer, et al.European Journal of Cancer (Oxford, England : 1990)|April 6, 2020
Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasisEleftheria Chorti, Theodora Kanaki, Lisa Zimmer, et al.European Journal of Cancer (Oxford, England : 1990)|March 27, 2026
Multi-modal computational data analysis for prediction of response to systemic treatment in metastatic melanomaVicky Parmar, Georg Lodde, Johannes Haubold, et al.European Journal of Cancer (Oxford, England : 1990)|February 20, 2017
Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunityRalf Gutzmer, Anika Koop, Friedegund Meier, et al.Pageof 31